Back to Capital Research Global Investors Capital Research Global Investors

DNLIDNLI
Showing 8 of 16 quarters

Position history for Capital Research Global InvestorsCapital Research Global Investors's holdings in DENALI THERAPEUTICS INC

Capital Research Global Investors holds 2.6M shares of DNLI (DENALI THERAPEUTICS INC), worth $66M as of 2026-Q2. The position was increased (+2.0% shares). DNLI represents 0.0% of Capital Research Global Investors's portfolio.

Current Value

$66M

Current Shares

2.6M

Total Value Change

-$164.4M

Total Shares Change

-5.3M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2.6M
+2.0%
$66M0.0%$25.72
30
2026-Q1
Decreased
2.5M
-32.6%
$48.3M0.0%$20.02
0
2025-Q4
Decreased
3.7M
-21.7%
$61.6M0.0%$16.41
0
2025-Q3
Increased
4.8M
+0.2%
$69.1M0.0%$14.52
30
2025-Q2
Decreased
4.8M
-0.3%
$66.5M0.0%$14.10
0
2025-Q1
Decreased
4.8M
-13.0%
$64.8M0.0%$14.78
0
2024-Q4
Decreased
5.5M
-30.8%
$111.6M0.0%$20.24
0
2024-Q3
Increased
7.9M
+11.0%
$230.4M0.0%$29.43
34

Other major holders of DNLI: BAILLIE GIFFORD & CO, BNP PARIBAS FINANCIAL MARKETS

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used